Titan is a specialty pharmaceuticals company that develops therapeutics for select chronic diseases utilizing its innovative, long-term, continuous drug delivery platform, ProNeura. The company's lead product is Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction. The U.S. Food and Drug Administration approved Probuphine on May 26, 2016. Probuphine is the first marketed product to provide maintenance treatment of opioid addiction continuously for six months following a single administration procedure. Source
No articles found.
CARROT is a fitness app that rewards users financially for walking and meeting per...
CARROT is a fitness app that rewards users fina...
Avenue Therapeutics, Inc., a Fortress Biotech (NASDAQ: FBIO) Company, is a special...
Avenue Therapeutics, Inc., a Fortress Biotech (...
A patient that is diagnosed with cancer today will have a genetic screen on their ...
A patient that is diagnosed with cancer today w...
Esperion is a pharmaceutical company passionately committed to developing and comm...
Esperion is a pharmaceutical company passionate...
Flexion Therapeutics is a biopharmaceutical company focused on the development and...
Flexion Therapeutics is a biopharmaceutical com...
Autolus is a clinical-stage, biopharmaceutical company, focused on the development...
Autolus is a clinical-stage, biopharmaceutical ...
Adial Pharmaceuticals, Inc. ("the Company") is a clinical-stage biopharmaceutical ...
Adial Pharmaceuticals, Inc. ("the Company") is ...
Join the National Investor Network and get the latest information with your interests in mind.